Loading...
Docoh
Log in Free sign up

Teva- Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Company profile

Ticker
TEVA, TEVJF
Exchange
NYSE
Website
www.tevapharm.com
CEO
Kaare Schultz
Employees
Incorporated
Israel
Location
Israel
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie • Warner Chilcott ...
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
0000818686
Corporate docs
Subsidiaries
Actavis Group • Actavis International Limited • Mepha Schweiz AG • Merckle GmbH • Ratiopharm GmbH • Teva API B.V. • Teva Canada Limited • Teva Capital Services Switzerland GmbH • Teva Czech Industries s.r.o • Teva Health GmbH ...

TEVA stock data

News

From Benzinga Pro
FDA Alerts Patients, Caregivers, And Health Care Providers Of Cross-Compatibility Issues With Autoinjector Devices That Are Optional For Use With Glatiramer Acetate Injection
18 Aug 22
Received Reports That Using Autoinjector Not Compatible With Specific Glatiramer Acetate Injection Drug Product Resulted In Missed, Partial Doses
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
18 Aug 22
Gainers
10 Health Care Stocks Whale Activity In Today's Session
17 Aug 22
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
17 Aug 22
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
17 Aug 22

Press releases

From Benzinga Pro
Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical?
18 Aug 22
NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, FCEL, SAVA, CDAK, and TEVA.
Thinking about buying stock in Genius Brands, Hill International, Tilray, Palisade Bio, or Teva Pharmaceutical?
17 Aug 22
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNUS, HIL, TLRY, PALI, and TEVA.
Thinking about buying stock in Teva Pharmaceutical, Geovax Labs, VNET Group, Stronghold Digital Mining, or Enphase Energy?
27 Jul 22
NEW YORK, July 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEVA, GOVX, VNET, SDIG, and ENPH.
Teva Reports Second Quarter 2022 Financial Results
26 Jul 22
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
12 Jul 22

Analyst ratings and price targets

Last 3 months
Current price
Average target
$11.00
Low target
$10.00
High target
$13.00
B of A Securities
Upgraded
Buy
$13.00
5 Aug 22
Goldman Sachs
Maintains
Neutral
$10.00
2 Aug 22
UBS
Initiated
Neutral
$10.00
14 Jun 22

Calendar

27 Jul 22
19 Aug 22
31 Dec 22

Financial summary

Financial statements Chart TEVA financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.09B 2.09B 2.09B 2.09B 2.09B 2.09B
Cash burn (monthly) 53M 28.75M 316.33M 80.08M (no burn) (no burn)
Cash used (since last report) 89.12M 48.34M 531.92M 134.66M n/a n/a
Cash remaining 2B 2.04B 1.56B 1.96B n/a n/a
Runway (months of cash) 37.8 71.0 4.9 24.4 n/a n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

TEVA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Aug 22 Eli Shani Ordinary Shares Option exercise Acquire M No No 0 1,581 0 19,741
10 Aug 22 Eli Shani Restricted Share Units Ordinary Shares Option exercise Dispose M No No 0 1,581 0 0
4 Aug 22 Barer Sol J Restricted Share Units Ordinary Shares Grant Acquire A No No 0 28,162 0 28,162
4 Aug 22 Crane Rosemary A Restricted Share Units Ordinary Shares Grant Acquire A No No 0 15,810 0 15,810
4 Aug 22 Elstein Amir Restricted Share Units Ordinary Shares Grant Acquire A No No 0 15,810 0 15,810
4 Aug 22 Halfon Jean Michel Restricted Share Units Ordinary Shares Grant Acquire A No No 0 15,810 0 15,810
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

TEVA institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • ARIAD Pharmaceuticals • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics
Management Discussion
  • The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2021 and 2020. For a comparison of our results of operations and financial condition for fiscal years 2020 and 2019, see “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2020 Annual Report on Form 10-K, filed with the SEC on February 10, 2021.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: administering, Alabama, alfa, beclomethasone, Bulgarian, Chewable, closure, comparedto, constant, deduction, dipropionate, forint, howthe, Hungarian, insolvent, lev, lieu, memorializing, Methylphenidate, milliondue, mL, modakafusp, Mozobil, Native, payup, Pemetrexed, Plerixafor, Quillichew, restructuringincome, resubmission, TAK, TEV, threeidentified, Turkey
Removed: Absent, anticipated, appointed, confidential, Corporation, dated, inhalation, maturing, mechanism, Mexican, misappropriating, negotiate, pace, passage, performed, raw, recent, stocking, strike, tranche, Truxima
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
27 Jul 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
9 Feb 22
10-Q
2021 Q3
Quarterly report
27 Oct 21
10-Q
2021 Q2
Quarterly report
28 Jul 21
10-Q
2021 Q1
Quarterly report
28 Apr 21
10-K
2020 FY
Annual report
10 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
Current reports
View all
8-K
Key financial highlights and outlook
26 Jul 22
8-K
Amendments to Articles of Incorporation or Bylaws
23 Jun 22
8-K
Results of Operations and Financial Condition
3 May 22
8-K
Departure of Directors or Certain Officers
24 Feb 22
8-K
Results of Operations and Financial Condition
9 Feb 22
8-K
Departure of Directors or Certain Officers
24 Nov 21
8-K
Entry into a Material Definitive Agreement
10 Nov 21
8-K
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
4 Nov 21
8-K
Other Events
2 Nov 21
8-K
Results of Operations and Financial Condition
27 Oct 21
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
4 Nov 21
FWP
Free writing prospectus
2 Nov 21
424B3
Prospectus supplement
27 Oct 21
S-3ASR
Automatic shelf registration
27 Oct 21
424B3
Prospectus supplement
17 Aug 20
S-4
Registration of securities issued in business combination transactions
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
Proxies
View all
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
PRE 14A
Preliminary proxy
15 Mar 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
16 Apr 19
Other
View all
SD
Conflict minerals disclosure
25 May 22
SD
Conflict minerals disclosure
20 May 21
UPLOAD
Letter from SEC
20 Apr 21
CORRESP
Correspondence with SEC
14 Apr 21
UPLOAD
Letter from SEC
21 Mar 21
EFFECT
Notice of effectiveness
18 Aug 20
SD
Conflict minerals disclosure
14 Aug 20
CORRESP
Correspondence with SEC
12 Aug 20
CORRESP
Correspondence with SEC
12 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
Ownership
View all
4
TEVA PHARMACEUTICAL INDUSTRIES / Eli Shani ownership change
11 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Tal Zvi Zaks ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Janet S. Vergis ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Ronit Satchi-Fainaro ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Nechemia Jacob Peres ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Perry Nisen ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / ROBERTO MIGNONE ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / GERALD M LIEBERMAN ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Jean Michel Halfon ownership change
8 Aug 22
4
TEVA PHARMACEUTICAL INDUSTRIES / Amir Elstein ownership change
8 Aug 22

Patents

View all
Utility
Solid State Forms of Tafamidis and Salts Thereof
18 Aug 22
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Utility
Solid State Forms of Relugolix
21 Jul 22
The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof.
Utility
Solid State Forms of SAGE-217 and Processes for Preparation Thereof
14 Jul 22
The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217:Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof.
Utility
Solid state forms of lumateperone ditosylate salt
17 May 22
Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.
Utility
Solid State Forms of Ripretinib
12 May 22
The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.

Transcripts

View all
2022 Q2
Earnings call transcript
27 Jul 22
2022 Q1
Earnings call transcript
3 May 22
2021 Q4
Earnings call transcript
9 Feb 22
2021 Q3
Earnings call transcript
27 Oct 21
2021 Q2
Earnings call transcript
28 Jul 21
2021 Q1
Earnings call transcript
28 Apr 21
2021 Q1
Earnings call transcript
28 Apr 21
2020 Q4
Earnings call transcript
10 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20

Reddit threads

View all